More surprisingly, HK2 antagonists, including ablation of glycolytic genes or treatment with 3-bromopyruvate, significantly relieved the severity of several arthritis models.[12,47] Targeting a specific intracellular compartment of HK2 (i.e., nucleus, cytosol, or mitochondria) will provide a selective way to block the harmful effect of the enzyme in RA without affecting the glucose metabolism of normal cells.[11] Therefore, HK2 is an attractive and selective target for the treatment of arthritis and is safer than global glucose metabolism inhibition. This evidence concerns the gene HK2 and arthritic joint disease.